Drug Profile
Ustekinumab biosimilar - BioXpress Therapeutics
Latest Information Update: 29 Dec 2021
Price :
$50
*
At a glance
- Originator BioXpress Therapeutics
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Antiulcers; Monoclonal antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Plaque psoriasis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Plaque-psoriasis in Switzerland (SC, Injection)
- 16 Aug 2013 Preclinical trials in Plaque psoriasis in Switzerland (SC)